A distinctive chromosomal abnormality in EBV-positive PTLD is the gain of 9p21, which causes changes in cyclin-dependent kinase inhibitor 2A (CDKN2A) expression and thus changes in cell cycle regulation [12]. This evidence concerns the gene CDKN2A and post-transplant lymphoproliferative disease.